Nestle Defends Extra Sugar In Cerelac Sold In India Vs Europe
Every country has a different set of guidelines. In some parts of the world, the quantity is less and in other sections, it is more, according to Suresh Narayanan, managing director of Nestle India Ltd.
The fast-moving consumer goods company was embroiled in a controversy earlier this month, as Swiss investigative agency Public Eye claimed that the company's baby food products contained more sugar in developing countries like India than the ones sold in the US and Europe. The agency had claimed that Cerelac contained an average of nearly 3 grammes of added sugar per serving.
Nestle India has a strong dominance in the infant food market. The company says that it is within the limit set by the Food Safety and Standards Authority of India, and the problem would have been when the required content would be below that offered in Europe.
"If my feed was giving less than what is given by a comparable feed in Europe, then you can say that you are shortchanging the children in India. That is not the case," Narayanan told NDTV Profit.
There are global guidelines and one can assume that infants across the globe require the same amount of nutrients. Babies need more energy-dense food because of the growth spurt and the quantity of the product is within the specified limit, he said.
Over time, the company has reduced its added sugar quantity by 30% and has plans to reduce it further.
"Nutrition content delivery of a product is as important as what goes into it," the MD said.
The company is on a journey to ensure that it can give good and balanced food, and any knee-jerk reaction could be detrimental to this cause, Narayanan said while talking about being part of the 'Eat Right' campaign.
Watch The Full Video Here:
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.